- 24/7 Wall St.•5 hours ago
Catabasis Pharmaceuticals shares skyrocketed on Thursday following an announcement that it would be partnering with Sarepta Therapeutics for a joint research collaboration.
- American City Business Journals•6 hours ago
Sarepta Therapeutics on Thursday morning announced a research partnership with another Cambridge biotech focused on Duchenne muscular dystrophy, which CEO Ed Kaye said may be the first of several such deals. Fresh off the U.S. approval of its drug, Exondys51, Sarepta (SRPT) officials said the company plans to test that drug in combination with an anti-inflammatory drug being developed at Catabasis Pharmaceuticals (CATB) in mice. While no financial details of the collaboration were released, Kaye said they want to see if the two drugs together work better to help slow the damage to muscles.
- Motley Fool•7 hours ago
Hit-or-miss data, delays, and contentious debate preceded the FDA's green-lighting of the first drug to target the cause of Duchenne muscular dystrophy. Meanwhile, a disappointing data readout stops one vaccine maker in its tracks.
Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||60.98 x 100|
|Ask||61.80 x 100|
|Day's Range||60.12 - 63.10|
|52wk Range||8.00 - 63.73|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-11.39|
|Avg Vol (3m)||4,071,681|
|Dividend & Yield||N/A (N/A)|